JPRN-UMIN000008404已完成未知
Extension of Tocilizumab Dose Intervals in Patients with Low to Moderate Disease Activity Rheumatoid Arthritis using IL-6 Serum Level as Starting Criteria. - Extension of Tocilizumab Dose Intervals in Patients with Rheumatoid Arthritis using IL-6 Serum Level Criteria.
Japan Labour Health and Welfare Organization, Yokohama Rosai Hospital0 个研究点目标入组 50 人开始时间: 2012年7月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patient who has no contraindications to methotrexate or to tocilizumab. 2) Patients who are inadequate to enter this trail due to the other reasons by physicians judgments.
研究者
相似试验
已完成
不适用
Tocilizumab long-term extension trial in patients with adult onset stillAdult onset still diseaseJPRN-UMIN000018414Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine34
招募中
1 期
Extending omalizumab treatment intervals in patients with chronic spontaneous urticaria (EXOTIC trial)Chronic spontaneous urticariaCTIS2023-506187-14-00Bispebjerg Hospital40
已完成
不适用
ong-term Safety of treatment with tocilizumab in the refractory patients with Takayasu ArteritisTakayasu arteritisJPRN-UMIN000025943Osaka Unversity9
已完成
不适用
EXTENDED SCHEDULE OF GROWING DOSES OF TEMOZOLOMIDE COMPARED TO DACARBAZINE FOR METASTASIC MELANOMA TREATMENT STAGE IV: RANDOMIZED STUDY OF PHASE III OF THE MELANOMA GROUP OF THE EORTC-C439 Malignant melanoma of skin, unspecifiedMalignant melanoma of skin, unspecifiedC439PER-083-04SCHERING PLOUGH RESEARCH INSTITUTE,
已完成
不适用
Clinical trial of long term efficacy for tocilizumab in systemic sclerosis and sclerodermatous chronic GVHDThe patients with systemic sclerosis or sclerodermatous chronic GVHD.JPRN-UMIN000022624Kanazawa University Hospital5